Citi Pharma Ltd’s (PSX: CPHL) wholly owned subsidiary, Citi Veterinary Limited, has formally commenced trading operations.
The Company is initially launching 32 veterinary products including vaccines, with Letters of Credit (LCs) already established for 8 products to ensure timely availability and supply, the company said in a notice to the Pakistan Stock Exchange (PSX) on Friday.
For the financial year 2025-26, Citi Veterinary Limited is projecting an expected turnover of approximately Rs. 1,500 million with a gross profit margin of 13%.
The company’s strong and long-standing supply partnerships in China will play a vital role in ensuring consistent and reliable supply availability in Pakistan’s veterinary healthcare market. Our supply chain partners in China have already established dedicated veterinary divisions and have strongly encouraged Citi Veterinary Limited to tap into Pakistan’s veterinary sector. Looking ahead, Citi Veterinary Limited is ambitiously planning to scale operations and achieve a turnover target of Rs. 10 billion within the next three years, the notice said.
On the production side, Citi Veterinary Limited has already submitted the layout plan with the Drug Regulatory Authority of Pakistan (DRAP) and the inspection is expected to be held in December 2025.
Read more: Citi Pharma Submits Offer to Acquire Top Pakistani Pharma
Allied facilities are already in place, and the company has acquired locally manufactured machinery while also establishing LCs for the import of additional machinery. With these measures in place, the production facility is expected to be ready for use, with trial production commencing by the end of Q4 of FY 2025-26 and the commercial production initiating from the start of FY 2026-27. Furthermore, the Company is planning to establish Pakistan’s first dedicated veterinary API plant during FY 2026-27, marking a pioneering step in the country’s veterinary pharmaceutical industry.
Upon commencement of in-house production, the company anticipates an increase in its gross profit margin to approximately 25%, reflecting stronger value addition and enhanced operational efficiency, it added.
Citi Veterinary Limited is confident that this milestone will mark the beginning of a new growth chapter, contributing significantly to Pakistan’s veterinary pharmaceutical industry and further strengthening Citi Pharma Limited’s diversified portfolio, the notice said.
